Navigation Links
Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Date:11/13/2008

with a corresponding negative predictive value of 99.1%. Patients with CIN2 are at risk of developing cervical cancer, however this risk is not as high as it is for those diagnosed with CIN3.

-- When compared to the ASC-US/LSIL Triage Study (ALTS), the Cervista HPV high-risk test has a comparable specificity to the test used in that study. The ALTS trial is the best comparative trial for the Cervista HPV high-risk trial based on similarities in trial design.

The Cervista HPV high-risk test has additional advantages including:

-- The Cervista HPV high-risk test has demonstrated a low indeterminate rate (i.e. inability of the test to give a result) of less than 1% and no cross reactivity with commonly reported low-risk HPV types.

-- An internal control that minimizes the potential for a false negative result due to insufficient sample cellularity.

-- Small volume of liquid-based cytology sample required for HPV testing. Hologic believes that this will reduce the percentage of "quantity not sufficient" samples that are burdensome to the lab, physicians and patients alike.

-- Workflow advantages for the laboratory. The Cervista HPV high-risk test requires minimal hands on time, and yields a rapid time to results.

In addition to the results for the Cervista HPV high-risk test, Hologic also announced today the clinical trial results for the Cervista 16/18 test, a genotyping test for high-risk HPV types 16 and 18, which are responsible for approximately 70% of all cervical cancers. The Cervista(R) 16/18 test is also pending FDA approval. Similar to the high risk screening test, the Cervista 16/18 test results were compared to CIN2 and CIN3 clinical end-points. Two potentially important findings were Negative Predictive Values for 99.5% for CIN3 and 97.7% for CIN2+. Recent consensus guidelines released by the American Society for Colposcopy and Cervical Pathology (ASCCP) in 2007 stated that "...it would be reasonable to util
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
2. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
3. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
6. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Immunosyn Corporation Releases SF-1019 Study Results
11. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Astellas has appointed James Kellerman ... the Americas. Kellerman will report directly to Linda ... Astellas. In his new role, Kellerman will lead a ... and manage the region,s intellectual property matters, coordinating closely ... very pleased to welcome Jim to Astellas. Jim brings ...
(Date:9/2/2014)... Sept. 2, 2014  Numotion is pleased to announce the ... of Directors. Mark is a 30-year retired ... positions across the organization and was a GE Company Officer ... Mark spent many years running business units within GE Healthcare, ... Healthcare Americas. "We are delighted to welcome ...
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
Breaking Medicine Technology:Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- A leading group ... of the major form of advanced breast cancer. ... to drugs that target the HER2 protein, the American ... news release. Almost 80 percent of women ... noted. "In releasing this guideline, our aim is ...
(Date:9/2/2014)... Doctors trained in locations with less intensive (and expensive) ... clinical decisions that spare patients unnecessary and excessive medical ... Internal Medicine . , "Growing concern about the costs ... assessing physicians, ability to avoid the provision of unnecessary ... Outcomes Group and The Dartmouth Institute for Health ...
(Date:9/2/2014)... When weather conditions are right, tornadoes can occur ... a path of destruction. In fact, the United States leads ... tornadoes per year. Rainbow International offers the following safety tips ... , Select a safe place such as ... with no windows to stay during the storm. If a ...
(Date:9/2/2014)... 2014 Alliance Strategies Group, LLC, an ... marketing is pleased to announce it is bringing two ... Freedom as well as The Red Report ... one million concerned Americans who can be reached via ... are honored to continue providing our clients and advertisers ...
Breaking Medicine News(10 mins):Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3
... increasing as more and younger people dye their hair, warn ... face and, in severe cases, facial swelling may occur. ... para-phenylenediamine (PPD) and other related agents. During the 20th century, ... it was banned from hair dyes in Germany, France, and ...
... diphenyl trichloroethane is the best pesticide and also an established carcinogen. ... at a very high// level even after many years of its ... ,The high level of DDT in the sea is due ... into local sewers which eventually lead into the sea. This has ...
... An intervention to improve communication between clinicians in the ... dying patient significantly reduces feelings of stress,// anxiety, and ... that appears in the February 1, 2007 issue of ... ,The study, funded in part by the National Institute ...
... King County have been diagnosed with a strain of HIV ... concerned it could spread further.// ,At least two ... another type has limited effectiveness, officials from Public Health — ... there can be more infections, and the gay community is ...
... wheat variety have led to a major advance in breeding ... papers published in the journal Plant Physiology researchers describe the ... work by excluding salt from different parts of the plant: ... discovery of the two genes is the subject of international ...
... Although the overall cancer death rate in African Americans has ... 35 percent higher in African American men and 18// percent ... women in the most recent time period (2003). ... past 10 years because rates have decreased faster in African ...
Cached Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:New HIV Threat Found in King County 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2Health News:Cancer Death Rates High in African-Americans 2
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTP/1Q-PAL chairs are recommended for the ... room, static control, health care and ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: